يعرض 1 - 10 نتائج من 12 نتيجة بحث عن '"Bart A. van de Wiel"', وقت الاستعلام: 0.97s تنقيح النتائج
  1. 1
    Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

    المؤلفون: Bart A. van de Wiel, Judith M. Versluis, Robyn P. M. Saw, Sydney Ch'ng, C. Blank, Bastian Schilling, Irene L.M. Reijers, Richard A. Scolyer, Georgina V. Long, Michel W.J.M. Wouters, Alexander C.J. van Akkooi, Elisa A. Rozeman, Alexander M. Menzies

    المصدر: European Journal of Cancer. 148:51-57

    مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Ipilimumab, Metastasis, Neoplasms, Multiple Primary, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Melanoma, Lymph node, Neoadjuvant therapy, Aged, Neoplasm Staging, Retrospective Studies, business.industry, Middle Aged, medicine.disease, Neoadjuvant Therapy, Survival Rate, Clinical trial, Nivolumab, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Lymphadenectomy, Neoplasm Recurrence, Local, business, Follow-Up Studies, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0cd6cfcc041a55a4244871ca4c62202Test
    https://doi.org/10.1016/j.ejca.2021.02.012Test


    أضف إلى المفضلة
  2. 2
    Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

    المؤلفون: Christian U. Blank, Rodabe N. Amaria, Jennifer A. Wargo, Bart A. van de Wiel, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Alexander C. Huang, Xiaowei Xu, Richard A. Scolyer, Tara C. Mitchell, Giorgos C. Karakousis, Alexander C.J. van Akkooi, Michael A. Davies, Andrew J. Spillane, Elisa A. Rozeman, Alexander M. Menzies, Robyn P. M. Saw, Michael T. Tetzlaff, Ahmad A. Tarhini, Thomas E. Pennington, Elizabeth M. Burton, Paolo A. Ascierto, Serigne Lo

    المصدر: Nature Medicine. 27:301-309

    مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Surrogate endpoint, Melanoma, medicine.medical_treatment, Ipilimumab, General Medicine, Immunotherapy, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Targeted therapy, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Nivolumab, business, Neoadjuvant therapy, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::826ffd3ff8235e1e6c027f5367069a0cTest
    https://doi.org/10.1038/s41591-020-01188-3Test


    أضف إلى المفضلة
  3. 3
    Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial

    المؤلفون: Michel W.J.M. Wouters, Sandra Adriaansz, Christian U. Blank, Bernies van der Hiel, Willem M.C. Klop, Bart A. van de Wiel, Johannes V. Van Thienen, Stephanie A. Blankenstein, Karolina Sikorska, Harm van Tinteren, Maartje W. Rohaan, Alexander C.J. van Akkooi, Winan J. van Houdt, Sofie Wilgenhof, Max J. Lahaye, A. Sari, Lindsay G Grijpink-Ongering, John B. A. G. Haanen

    المصدر: Annals of Surgery, 274(2), 383-389. LIPPINCOTT WILLIAMS & WILKINS

    مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, medicine.medical_treatment, unresectable, Pyrimidinones, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Stage IIIC, Prospective Studies, Melanoma, Cancer staging, Aged, Neoplasm Staging, Netherlands, Trametinib, business.industry, neoadjuvant, MEK inhibitor, Imidazoles, Dabrafenib, Cytoreduction Surgical Procedures, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Neoadjuvant Therapy, BRAF mutation, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Surgery, Female, Radiology, business, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c8330f3776251538255964ce6c8db0Test
    https://pubmed.ncbi.nlm.nih.gov/33843797Test


    أضف إلى المفضلة
  4. 4
    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    المؤلفون: Lindsay G Grijpink-Ongering, Sandra Adriaansz, Pia Kvistborg, Christian U. Blank, John B. A. G. Haanen, Annemarie Bruining, Bart A. van de Wiel, Karolina Sikorska, Daisy Philips, Lorenzo F. Fanchi, Sarah Warren, Ton N. Schumacher, Oscar Krijgsman, Daniel S. Peeper, Annegien Broeks, Harm van Tinteren, Elisa A. Rozeman, H. Mallo, Marlous van den Braber, Loes M. Pronk, Sylvia ter Meulen, Alexander C.J. van Akkooi, Johannes V. Van Thienen, Rachel M. Gittelman

    المصدر: Nature Medicine. 24:1655-1661

    مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Melanoma, Ipilimumab, General Medicine, medicine.disease, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Regimen, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Nivolumab, business, Adverse effect, Adjuvant, Neoadjuvant therapy, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::296148c6d18ab7822871b24bd03c1594Test
    https://doi.org/10.1038/s41591-018-0198-0Test


    أضف إلى المفضلة
  5. 5
    Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)

    المؤلفون: John B. A. G. Haanen, Lindsay G Grijpink-Ongering, Christian U. Blank, Ellen Kapiteijn, Jacqueline E. van der Wal, Mark A.J. Meier, Bart A. van de Wiel, H. Mallo, Harm van Tinteren, Ferry Lalezari, Annegien Broeks, Trieu-My Van, Karolina Sikorska, Jason Reeves, Elisa A. Rozeman, Sarah Warren, Warner Prevoo, Johannes V. Van Thienen

    المصدر: Melanoma Research
    Melanoma Research, 30(3), 252-260. LIPPINCOTT WILLIAMS & WILKINS

    مصطلحات موضوعية: Adult, Male, Uveal Neoplasms, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Radiofrequency ablation, Ipilimumab, Dermatology, Gastroenterology, law.invention, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, law, Internal medicine, checkpoint inhibition, medicine, Humans, Adverse effect, Melanoma, Aged, Radiofrequency Ablation, Dose limiting toxicity, business.industry, Liver Neoplasms, Middle Aged, medicine.disease, Combined Modality Therapy, Progression-Free Survival, 030104 developmental biology, Oncology, Liver lesion, 030220 oncology & carcinogenesis, Cohort, Cutaneous melanoma, radio frequency ablation, Female, immunotherapy, uveal melanoma, business, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439460a026eeea14fea56c84315ff7c1Test
    https://hdl.handle.net/1887/3184767Test


    أضف إلى المفضلة
  6. 6
    Abstract 3271: Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial

    المؤلفون: Christian U. Blank, Kerwin F. Shannon, Bart A. van de Wiel, Irene L.M. Reijers, Andrew J. Spillane, María Jesús González González, Harm van Tinteren, Richard A. Scolyer, Elisa A. Rozeman, Johan Hansson, Karolina Sikorska, Hanna Eriksson, Alexander C.J. van Akkooi, Carolien Bierman, Alexander M. Menzies, Georgina V. Long, Judith M. Versluis, Robyn P. M. Saw

    المصدر: Cancer Research. 80:3271-3271

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Cancer, Ipilimumab, medicine.disease, Gastroenterology, Regimen, Oncology, Internal medicine, Cohort, medicine, Pathologic Response, Stage III melanoma, Nivolumab, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8ce92f1132d4d004283bd3902be08e2dTest
    https://doi.org/10.1158/1538-7445.am2020-3271Test


    أضف إلى المفضلة
  7. 7
    Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

    المؤلفون: Judith M. Versluis, Ron M. Kerkhoven, Winan J. van Houdt, Richard A. Scolyer, Christian U. Blank, John B. A. G. Haanen, Irene L.M. Reijers, Andrew J. Spillane, Oscar Krijgsman, Karolina Sikorska, Bart A. van de Wiel, Alexander M. Menzies, Hanna Eriksson, Annegien Broeks, María Jesús González González, Robyn P. M. Saw, Elisa A. Rozeman, Georgina V. Long, Ton N. Schumacher, Alexander C.J. van Akkooi, Petros Dimitriadis, Esmée P. Hoefsmit, Carolien Bierman

    المصدر: Cancer Research. 80:3412-3412

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Melanoma, Cancer, Ipilimumab, medicine.disease, Gastroenterology, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, Stage III melanoma, Nivolumab, business, Adjuvant, Neoadjuvant therapy, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::64b9180c53a7818b8061f74aa4a507d6Test
    https://doi.org/10.1158/1538-7445.am2020-3412Test


    أضف إلى المفضلة
  8. 8
    Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma

    المؤلفون: Christian U. Blank, Willem M.C. Klop, Richard A. Scolyer, Alexander M. Menzies, Annegien Broeks, Elisa A. Rozeman, Robyn P. M. Saw, Oscar Krijgsman, Georgina V. Long, Irene L.M. Reijers, Petros Dimitriadis, Esmée P. Hoefsmit, Andrew J. Spillane, Bart A. van de Wiel, María Jesús González González, Lindsay G Grijpink-Ongering, Ron M. Kerkhoven, Hanna Eriksson, Karolina Sikorska, Alexander C.J. van Akkooi

    المصدر: Journal of Clinical Oncology. 38:10015-10015

    مصطلحات موضوعية: Oncology, Cancer Research, Schedule, medicine.medical_specialty, Toxicity data, business.industry, Ipilimumab, 03 medical and health sciences, 0302 clinical medicine, Early results, Dosing schedules, 030220 oncology & carcinogenesis, Internal medicine, medicine, Stage III melanoma, Dosing, Nivolumab, business, 030215 immunology, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f180171c2db0d6119a143cb5e06d49d3Test
    https://doi.org/10.1200/jco.2020.38.15_suppl.10015Test


    أضف إلى المفضلة
  9. 9
    Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study

    المؤلفون: Alexander M. Menzies, Christian U. Blank, Sten Cornelissen, Bart A. van de Wiel, María Jesús González González, Richard A. Scolyer, Georgina V. Long, Linda J.W. Bosch, Lindsay G Grijpink-Ongering, Jasper Bouwman, Annegien Broeks, Petros Dimitriadis, Oscar Krijgsman, Alexander C.J. van Akkooi, Judith M. Versluis, Elisa A. Rozeman, Marloes van Dijk, Irene L.M. Reijers, Andrew J. Spillane, Disha Rao

    المصدر: Journal of Clinical Oncology. 38:TPS10087-TPS10087

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Ipilimumab, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Pathologic Response, Interferon gamma, Stage III melanoma, Nivolumab, business, 030215 immunology, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9636f93b3258fdc415785bc1248f34b3Test
    https://doi.org/10.1200/jco.2020.38.15_suppl.tps10087Test


    أضف إلى المفضلة
  10. 10
    Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial

    المؤلفون: Alexander M. Menzies, Ellen Kapiteijn, Alexander C.J. van Akkooi, Lars Bastholt, Christian U. Blank, Elisa A. Rozeman, Willem M.C. Klop, Bart A. van de Wiel, Irene L.M. Reijers, Andrew J. Spillane, Karijn P M Suijkerbuijk, Geke A. P. Hospers, Hanna Eriksson, James Larkin, Georgina V. Long, Inge Marie Svane, Henrik Schmidt, Astrid A M van der Veldt, Richard A. Scolyer

    المصدر: Reijers, I, Rozeman, E A, Menzies, A M, De Wiel, B A V, Eriksson, H, Suijkerbuijk, K, Van Der Veldt, A A M, Kapiteijn, E, Hospers, G, Klop, W M C, Spillane, A, Scolyer, R A, Svane, I M, Bastholt, L, Schmidt, H, Larkin, J M G, Van Akkooi, A C J, Long, G V & Blank, C U 2019, ' Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial ', Journal of Clinical Oncology, vol. 37, no. 15 Suppl., TPS9605 . https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS9605Test

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Ipilimumab, Relapse free survival, Immune checkpoint, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Adjuvant therapy, Stage III melanoma, Nivolumab, business, Adjuvant, 030215 immunology, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c98b636b3dd00b5a364206cf1137b94Test
    https://doi.org/10.1200/jco.2019.37.15_suppl.tps9605Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث